Biocompatibility and anticancer activity of L-phenyl alanine-coated iron oxide magnetic nanoparticles as potential chrysin delivery system
Source abstract
Abstract
In this project, we described the production of chrysin-loaded L-phenyl alanine (Phe)-coated iron oxide magnetic nanoparticles (chrysin@Phe@IOMNs). chrysin@Phe@IOMNs were characterized by X-ray diffraction, thermogravimetric analysis, fourier transform infrared spectroscopy, vibrating sample magnetometer, and transmission electron microscopy techniques. Next, hemocompatibility and biocompatibility of Phe-coated IOMNs were determined by hemolysis and MTT assays on HFF-2 and HEK-293 cell lines, respectively. Finally, the anticancer activity of chrysin@Phe@IOMNs was examined on MCF-7 cell line. The outcomes direct that as-prepared nanocarriers are nontoxic and biocompatible and also chrysin@Phe@IOMNs are appropriate for chrysin delivery and other hydrophobic therapeutic agents.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Flavonoids in Medical Research · Curcumin's Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. 10.1039/B917195A10.1039/B917195A ↗
2. 10.1016/j.jallcom.2009.04.10310.1016/j.jallcom.2009.04.103 ↗
3. 10.1039/C6NJ03332F10.1039/C6NJ03332F ↗
4. 10.1002/jbm.a.3636410.1002/jbm.a.36364 ↗
5. 10.1002/aoc.406910.1002/aoc.4069 ↗
6. 10.1021/acs.jpcc.6b0318010.1021/acs.jpcc.6b03180 ↗
7. 10.1016/j.cap.2008.08.02710.1016/j.cap.2008.08.027 ↗
8. 10.1016/j.matlet.2008.10.05710.1016/j.matlet.2008.10.057 ↗
9. 10.1039/C3TB21171A10.1039/C3TB21171A ↗
10. 10.1016/j.colsurfa.2013.08.04410.1016/j.colsurfa.2013.08.044 ↗
11. 10.1039/C5CS00541H10.1039/C5CS00541H ↗
12. 10.1007/s10904-017-0758-710.1007/s10904-017-0758-7 ↗
13. 10.3109/10717544.2013.87383710.3109/10717544.2013.873837 ↗
14. 10.1007/s40005-013-0098-810.1007/s40005-013-0098-8 ↗
15. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
16. 10.3109/0284186920908890210.3109/02841869209088902 ↗
17. Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line10.3109/21691401.2015.1029633 ↗
18. 10.1016/j.bmcl.2005.09.00910.1016/j.bmcl.2005.09.009 ↗
19. 10.1016/j.bioorg.2017.12.03310.1016/j.bioorg.2017.12.033 ↗
20. 10.15171/apb.2015.07410.15171/apb.2015.074 ↗
21. 10.1039/c1nr10326a10.1039/c1nr10326a ↗
22. 10.1007/s11164-017-3204-010.1007/s11164-017-3204-0 ↗
23. 10.1016/j.ejpb.2014.03.01110.1016/j.ejpb.2014.03.011 ↗
24. 10.1039/C6RA00102E10.1039/C6RA00102E ↗
25. Development and characterization dual responsive magnetic nanocomposites for targeted drug delivery systems
26. 10.1097/00001648-199503000-0000910.1097/00001648-199503000-00009 ↗
27. 10.1016/j.apsusc.2015.11.25210.1016/j.apsusc.2015.11.252 ↗
28. Facile synthesis and characterization of l-aspartic acid coated iron oxide magnetic nanoparticles (IONPs) for biomedical applications10.1055/s-0043-120197 ↗
29. 10.1039/c2cs15315g10.1039/c2cs15315g ↗
30. 10.1080/21691401.2016.122865810.1080/21691401.2016.1228658 ↗
31. 10.1016/S0304-8853(00)01229-410.1016/S0304-8853(00)01229-4 ↗
32. 10.1016/j.ica.2012.01.05810.1016/j.ica.2012.01.058 ↗
33. 10.1007/s11164-013-1484-610.1007/s11164-013-1484-6 ↗
34. 10.1021/acs.jpcc.5b0719510.1021/acs.jpcc.5b07195 ↗
35. 10.1016/j.ijbiomac.2018.04.04310.1016/j.ijbiomac.2018.04.043 ↗